



Press release

SHL's Board appoints a Committee for the Examination of the Financial Statements

Tel Aviv / Zurich, 6 July 2017 – SHL Telemedicine Ltd. (SIX Swiss Exchange: SHLTN, OTCPK: SMDCY) ("SHL"), a leading provider and developer of advanced personal telemedicine solutions, announced that following the election of external directors of 28 June 2017, SHL's Board of Directors has appointed the committee for the Examination of Financial Statements (as such term is defined under Israeli law), replacing the special interim financial statements committee appointed on 12 May 2017. The elected members are, by alphabetical order, Mr. Yehoshua Abramovich, Prof. Amir Lerman, and Mr. Xuequn Qian, all of which have declared that they have the required capacity of reading and understanding financial statements as required under Israeli law.

About SHL Telemedicine

SHL Telemedicine is engaged in developing and marketing personal telemedicine systems and the provision of medical call center services, with a focus on cardiovascular and related diseases, to end users and to the healthcare community. SHL Telemedicine offers its services and personal telemedicine devices to subscribers utilizing telephonic and Internet communication technology. The Company operates in Israel, Germany, India and the United States in one business segment, Telemedicine services. SHL is listed on the SIX Swiss Exchange (SHLTN, ISIN: IL0010855885, Security No.: 1128957) and has an ADR program listed over-the counter; Symbol: SMDCY. For more information, please visit our web site at www.shl-telemedicine.com.

For further information please contact:

Martin Meier-Pfister, IRF Communications, Phone: +41 43 244 81 40, shl@irfcom.ch

Some of the information contained in this press release contains forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. SHL Telemedicine undertakes no obligation to publicly update or revise any forward-looking statements.